InflaRx N.V.

Contract manufacturing of biologics is one of the few weak points in the typically overwhelming advantage the US holds over Europe in bestowing the first approval for new drug products, a Pink Sheet

InflaRx’s share price is in freefall after the German biotech pulled the plug on its lead candidate vilobelimab after failing a late-stage study as a potential treatment for the rare skin condition po

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

The European Medicines Agency is due to decide this week whether to recommend pan-EU marketing authorization for several products, including two treatments that are yet to be approved anywhere in the